Back A A A Font Size Receive E-mail Alerts Press Releases

Firehawk® Presented at the 15th Malaysian Cardiovascular Interventional Symposium with Live Transmission (MYLIVE2018)


Petaling Jaya, Malaysia – From July 26 to July 28, the 15th Malaysian Cardiovascular Interventional Symposium with Live Transmission (MYLIVE2018) took place in Petaling Jaya, which is the biggest city in Selangor, Malaysia, and gathered more than 1,000 surgeons from Southeast Asia. The symposium was aimed to share the latest results of the researches on cardiovascular intervention, increase the understanding of cardiovascular diseases and promote the improvement in interventional techniques, with the help of exchanges between specialists and live streaming of surgeries. Shanghai MicroPort Medical (Group) Co., Ltd. ("MicroPort®") attended the symposium and held a Firehawk® Rapamycin Target Eluting Coronary Stent System ("Firehawk®") satellite symposium to demonstrate in full extent the innovative technology and outstanding performance of Firehawk® to the specialists in attendance.
On July 26, Dato Dr. Omar Ismail from Hospital Pulau Pinang delivered the opening remark for the satellite symposium, before introducing Firehawk® to the audience and praising MicroPort® for its relentless pursuit of technology development and honing the clinical studies. Afterwards, Professor William Wijns from National University of Ireland, Galway, who was the principal investigator in the latest TARGET All-Comers ("TARGET AC") trial of Firehawk®, gave the audience a videoed greeting, saying that the Firehawk® with internationally high level had been widely recognized by the top European interventional cardiologists. He also hoped that the attending experts could fully experience the excellent performance of Firehawk® at the symposium and bring high-quality medical solutions to the local patients. MicroPort® Clinical & Medical Affairs Vice President Ming Zheng, who is also head of the MicroPort® Knowledge & Action Institute, presented the global clinical trials of Firehawk® to the audience. He went into detail about the outstanding performance demonstrated by Firehawk® in the TARGET AC trial, which was a global multicenter randomized controlled study, from a perspective of the trial design.
During the satellite symposium, Dr. Ong Tiong Kiam from the Pusat Jantung Sarawak clinical study site introduced the TARGET Malaysia Registry trial of Firehawk® ("TARGET MR") and the latest progress. As part of the TARGET-series trials, TARGET MR, which is the second large-scale overseas trial of Firehawk® after the TARGET AC trial in Europe, is a prospective multicenter registry study jointly driven by MicroPort® and Ministry of Health of Malaysia. It is expected to enroll a total of 1,153 patients at 10 local clinical trial sites, with the primary endpoints being the Target Lesion Failure (TLF) at 12 months. Subsequently, with Dr. Liew Houng Bang from Queen Elizabeth II Hospital acting as the moderator, four junior surgeons, namely Dr. Ho Kian Hui, Dr. Faizal Khan, Dr. Lee Kuo Ting and Dr. Khaw Chee Sin, spoke about cases of coronary infarction, acute myocardial infarction, FFR-guided PCI in patients with multivessel diseases, and emergency PCI patient transfer and treatment. All of them gave favorable comments about the performance of Firehawk® in complex lesions, commending the cardiovascular interventional device for its world-class quality.
As a major country covered in China's Belt and Road Initiative, Malaysia has a strong demand for cardiovascular interventional products with a population of more than 30 million. Thus far, MicroPort® has obtained registration approvals from the Malaysian authorities for Firehawk®, FOXTROT™ Pro PTCA Balloon Catheter and FOXTROT™ NC PTCA Balloon Catheter. With an increasingly richer cardiovascular product line, MicroPort® has provided the local surgeries with more comprehensively therapeutic solutions, so as to benefit the local patients.

About MicroPort®

MicroPort Scientific Corporation (the "Group") is a leading medical device company with business focusing on innovating, manufacturing, and marketing high-quality and high-end medical devices globally. With a diverse portfolio of products now being used at an average rate of one for every 12 seconds in thousands of major hospitals around the world, the Group maintains world-wide operations in a broad range of business segments including Cardiovascular, Orthopedic, Cardiac Rhythm Management, Electrophysiological, Endovascular, Neurovascular, Surgical, Diabetes Care and Endocrinal Management, and others. MicroPort® is dedicated to becoming a patient oriented global enterprise improve and reshape patient lives through application of innovative science and technology.

For more information, please refer to:

Forward-Looking Statements

Some information contained on this website contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words "believe", "intend", "expect", anticipate", "project", "estimate", "predict", "is confident", "has confidence" and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort®'s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China.

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

All rights reserved.
Copyright © 1998-2018 MicroPort Scientific Corporation

Leanne Li
Board Secretary and Vice President of Corporate General Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600-6953


[Prev]:MicroPort® Firefighter™ PTCA Balloon Catheter Obtains Approval for Registration in Mexico
[Next]:MicroPort® Orthopedics Attends the First Edition of the Northeast Region Joint Surgery Summit Forum